Project title
Lactomezole, a safe and effective eradication therapy for H. Pylori without the use of antibiotics
Funding Program
EUROSTARS
Funding code
AVVALACT
11 089
Start date
April 3, 2017
Expected Completion
2020-04-02
Description
To develop a product, Lactomezole, as a new innovative standard of care for the management of dyspepsia and first line treatment for H. pylori infection, which is associated with dyspeptic and gastro-intestinal conditions, including gastric cancer. Lactomezole has significant OTC potential, as it will be the first proton pump inhibitor (PPI) plus prebiotic combo that has demonstrated eradication of H. pylori and normalization of GI tract microbiota without the use of antibiotics.